Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19826480 | 0.78 | TDP2 (0.42) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL19947472 | 0.78 | TDP2 (0.47) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL8943779 | 0.78 | ADAMTS5 (0.42) | ADAMTS5GAACXCR4MAOAMAOB | |
| SCHEMBL19826497 | 0.76 | CYP26A1 (0.45) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL12258527 | 0.72 | HDAC8 (0.47) | ADAMTS5CYP3A4GAACXCR4 | |
| SCHEMBL19826793 | 0.72 | HSD17B1 (0.57) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL18076565 | 0.72 | HSD17B1 (0.52) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL19961832 | 0.71 | TDP2 (0.47) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 | |
| SCHEMBL11683936 | 0.70 | TYR (0.43) | GAACXCR4 | |
| SCHEMBL18076597 | 0.70 | HSD17B1 (0.53) | TDP2HSD17B1HSD17B2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-02-16 | — | — | US | disclosed |
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| EP-3271320-B1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LTD (AU) | 2019-10-23 | — | — | EP | disclosed |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2019-09-05 | — | — | US | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-07-31 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| WO-2018018091-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-02-01 | — | — | WO | disclosed |
| EP-3271320-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | Vectus Biosystems Limited (AU) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016145479-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | VECTUS BIOSYSTEMS LIMITED (AU) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035775-B2 | Compositions for the treatment of fibrosis and fibrosis-related conditions | MMP1, COL1A1, COL2A1 | TDP2 4313/4885ADAMTS5 232/4885HSD17B1 881/4885 |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | TDP2 4361/4885ADAMTS5 521/4885HSD17B1 1399/4885 |
| US-20190270712-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | TDP2 4361/4885ADAMTS5 521/4885HSD17B1 1399/4885 |
| US-20180072682-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS | MMP1, COL1A1, COL2A1 | TDP2 4313/4885ADAMTS5 232/4885HSD17B1 881/4885 |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | TDP2 4361/4885ADAMTS5 521/4885HSD17B1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.